Last reviewed · How we verify
rhNGF
At a glance
| Generic name | rhNGF |
|---|---|
| Also known as | NGF, cenegermin |
| Sponsor | Dompé Farmaceutici S.p.A |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (PHASE3)
- A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease. (PHASE2)
- DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
- Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PHASE3)
- Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis (PHASE4)
- Corneal Neurotization vs. Cenergermin for Neurotrophic Keratitis: A Pilot Study (NA)
- DOMPE -MT Neurotrophic Keratitis (PHASE4)
- Corneal Nerves After Treatment With Cenegermin
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhNGF CI brief — competitive landscape report
- rhNGF updates RSS · CI watch RSS
- Dompé Farmaceutici S.p.A portfolio CI